Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Arthritis Care Res (Hoboken). 2021 Feb;73(2):180–187. doi: 10.1002/acr.24115

Table 2.

Association between self-reported family history of comorbidities and developing RA, ordered by strength of association

N (%)
Comorbidity RA Cases (N = 821) Controls (N = 2455) Unadjusted OR for RA (95% CI) Adjusted OR for RA (95% CI)*
Rheumatoid arthritis 272 (36) 379 (18) 2.56 (2.12,3.08) 2.44 (2.02,2.94)
HIV 9 (1) 11 (0.5) 2.47 (0.99,5.98) -
Pulmonary fibrosis 20 (3) 29 (1) 2.10 (1.17,3.72) 2.12 (1.16,3.80)
Rheum. autoimmune dz.** 82 (11) 143 (7) 1.84 (1.38,2.44) 1.89 (1.41,2.52)
Autism 24 (3) 44 (2) 1.66 (0.99,2.72) 1.62 (0.96,2.67)
Tuberculosis 34 (5) 68 (3) 1.52 (0.99,2.30) 1.51 (0.98,2.30)
Inflammatory bowel disease 62 (8) 129 (6) 1.49 (1.08,2.03) 1.45 (1.05,1.98)
Celiac disease 29 (4) 62 (3) 1.44 (0.91,2.24) 1.45 (0.91,2.27)
Osteoarthritis 403 (55) 1075 (47) 1.36 (1.15,1.61) 1.41 (1.19,1.68)
Fibromyalgia 74 (10) 168 (8) 1.39 (1.04,1.84) 1.40 (1.04,1.86)
Hyper/hypothyroidism 206 (28) 490 (23) 1.34 (1.11,1.62) 1.34 (1.10,1.63)
Other liver disease 61 (8) 137 (6) 1.36 (0.99,1.85) 1.29 (0.93,1.77)
Obstructive sleep apnea 205 (28) 503 (22) 1.32 (1.09,1.59) 1.28 (1.05,1.55)
Other mental illness 93 (13) 222 (10) 1.29 (0.99,1.66) 1.24 (0.95,1.61)
Migraine headaches 267 (36) 703 (32) 1.22 (1.02,1.45) 1.20 (1.00,1.43)
Asthma 232 (31) 607 (27) 1.20 (1.00,1.44) 1.20 (0.99,1.44)
COPD 125 (17) 304 (14) 1.27 (1.01,1.59) 1.19 (0.94,1.50)
Venous thromboembolism 125 (17) 319 (15) 1.20 (0.95,1.50) 1.18 (0.94,1.48)
Type 2 diabetes 214 (29) 723 (32) 0.85 (0.70,1.01) 0.81 (0.67,0.97)
Parkinson’s disease 44 (6) 182 (8) 0.71 (0.50,0.99) 0.70 (0.49,0.98)

CI = confidence interval, COPD = chronic obstructive pulmonary disease, dz = disease, HIV = human immunodeficiency virus, OR = odds ratio, RA = rheumatoid arthritis, rheum. = rheumatologic

*

Adjusting for age, sex, race, BMI, education, smoking (ever vs never). Bold values are statistically significant at p<0.01.

**

Prompted participants with the examples of scleroderma, lupus